Search Result
Results for "
calcium release
" in MedChemExpress (MCE) Product Catalog:
2
Biochemical Assay Reagents
Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-100430
-
|
Apoptosis
PDI
|
Cancer
|
CCF642 is a potent protein disulfide isomerases (PDI) inhibitor with an IC50 of 2.9 μM. CCF642 causes acute endoplasmic reticulum (ER) stress in multiple myeloma cells accompanied by apoptosis-inducing calcium release. CCF642 has broad anti-multiple myeloma activity .
|
-
-
- HY-101237
-
-
-
- HY-14657
-
-
-
- HY-N4323
-
|
Calcium Channel
|
Neurological Disease
Metabolic Disease
|
14-Deoxyandrographolide is a labdane diterpene with calcium channel blocking activity. 14-Deoxyandrographolide desensitizes hepatocytes to TNF-α-mediated apoptosis through the release of TNFRSF1A release .
|
-
-
- HY-B1559
-
|
|
|
Allethrin, a pyrethroid insecticide is a major mosquito repellent agent. Allethrin induces oxidative stress, apoptosis and calcium release in rat testicular carcinoma cells (LC540). Allethrin induces BCL-2, caspase-3 activation and release of intracellular calcium .
|
-
-
- HY-130575
-
|
Fluorescent Dye
|
Others
|
Fura-FF AM is a cell-permeable acetoxymethyl ester of fura-FF, a dluorescent calcium indicator. Fura-FF AM is hydrolyzed by intracellular esterases to release fura-FF in cells. Fura-FF is a difluorinated derivative of the calcium indicator fura-2. Compared to fura-2, fura-FF has a low affinity for calcium and is suitable for studying compartments with high concentrations of calcium.
|
-
-
- HY-112961
-
|
Potassium Channel
|
Others
|
Patiromer is an orally active and potent hyperkalemia inhibitor and a nonabsorbed potassium binder. Patiromer polymer is bound with calcium which is released in the colon in exchange for binding potassium .
|
-
-
- HY-101942
-
CM-4620
|
CRAC Channel
|
Neurological Disease
|
Zegocractin (CM-4620) is a calcium-release activated calcium-channel (CRAC channel) inhibitor, with IC50s of 119 nM and 895 nM for Orai1/STIM1 and Orai2/STIM1 channels, respectively .
|
-
-
- HY-15277
-
-
-
- HY-100168
-
BAPTA
Maximum Cited Publications
21 Publications Verification
|
Phospholipase
|
Others
|
BAPTA is a selective chelator for calcium. BAPTA, as calcium indicator, has high selectivity against magnesium and calcium. BAPTA is widely used as an intracellular buffer for investigating the effects of Ca 2+ release from intracellular stores or influx via Ca 2+-permeable channels in the plasma membrane. BAPTA can also inhibit phospholipase C activity independently of their role as Ca 2+ chelators .
|
-
-
- HY-N7395
-
-
-
- HY-103071
-
|
CRAC Channel
|
Inflammation/Immunology
|
GSK-5503A is a calcium-release activated calcium (CRAC) channel blocker. GSK-5503A effectively inhibits stromal interaction molecule 1 (STIM1) mediated Orai1 and Orai3 currents in vitro. GSK-5503A can be used for the research of asthma and allergic disorders .
|
-
-
- HY-100168B
-
|
Phospholipase
|
Others
|
BAPTA tetrapotassium is a selective chelator for calcium. BAPTA, as calcium indicator, has high selectivity against magnesium and calcium. BAPTA tetrapotassium is widely used as an intracellular buffer for investigating the effects of Ca 2+ release from intracellular stores or influx via Ca 2+-permeable channels in the plasma membrane. BAPTA tetrapotassium can also inhibit phospholipase C activity independently of their role as Ca 2+ chelators .
|
-
-
- HY-100168A
-
|
Phospholipase
|
Others
|
BAPTA tetrasodium is a selective chelator for calcium. BAPTA tetrasodium, as calcium indicator, has high selectivity against magnesium and calcium. BAPTA tetrasodium is widely used as an intracellular buffer for investigating the effects of Ca 2+ release from intracellular stores or influx via Ca 2+-permeable channels in the plasma membrane. BAPTA tetrasodium can also inhibit phospholipase C activity independently of their role as Ca 2+ chelators .
|
-
-
- HY-N7395A
-
-
-
- HY-121885
-
LMD-009
1 Publications Verification
|
CCR
|
Metabolic Disease
Endocrinology
|
LMD-009 is a selective CCR8 nonpeptide agonist. LMD-009 mediates chemotaxis, inositol phosphate accumulation, and calcium release in high potencies with EC50s from 11 to 87 nM .
|
-
-
- HY-103059
-
|
Calcium Channel
|
Cardiovascular Disease
|
SOICR-IN-1 (compound 32) is a store-overload induced calcium release (SOICR) inhibitor with an IC50 value of 14.6 μM. SOICR-IN-1 can be used for the research of cardiac arrhythmias .
|
-
-
- HY-108335
-
619C89; BW 619C89
|
Sodium Channel
Calcium Channel
|
Neurological Disease
|
Sipatrigine (619C89), a neuroprotective agent, is a glutamate release inhibitor, voltage-dependent sodium channel and calcium channel inhibitor, penetrating the central nervous system. Has the potential in the study for focal cerebral ischemia and stroke .
|
-
-
- HY-113920A
-
EU4093 free base
|
Calcium Channel
|
Metabolic Disease
|
Azumolene (EU4093 free base), a Dantrolene analog, is a muscle relaxant. Azumolene is a ryanodine receptor (RyR) modulator and inhibits the calcium-release through ryanodine receptor. Azumolene can be used for malignant hyperthermia research .
|
-
-
- HY-101013
-
S-Nitroso-N-acetylpenicillamine
|
Fluorescent Dye
|
Others
|
D-SNAP (S-Nitroso-N-acetylpenicillamine) can Generate nitric oxide and form superoxides spontaneously under physiological conditions and is often used to probe the cell stress response and stimulate calcium-independent synaptic vesicle release.
|
-
-
- HY-14752
-
SB 751689
|
CaSR
|
Metabolic Disease
Endocrinology
|
Ronacaleret (SB 751689) is an orally active, potent, and selective calcium-sensing receptor (CaSR) antagonist that stimulates endogenous parathyroid hormone release from the parathyroid glands. Ronacaleret (SB 751689) is used for the study of postmenopausal osteoporosis .
|
-
-
- HY-15104
-
SB 751689A
|
CaSR
|
Metabolic Disease
Endocrinology
|
Ronacaleret hydrochloride (SB 751689A) is an orally active, potent, and selective calcium-sensing receptor (CaSR) antagonist that stimulates endogenous parathyroid hormone release from the parathyroid glands. Ronacaleret hydrochloride (SB 751689A) is used for the study of postmenopausal osteoporosis .
|
-
-
- HY-N11691
-
Thapsigargicine
|
Others
|
Inflammation/Immunology
|
Thapsigargicin (Thapsigargicine) is a activator of mast cells and leukocytes. Thapsigargicin induces histamine release from rat peritoneal mast cells and human basophil leukocytes. Thapsigargicin increases the cytoplasmic free calcium level in intact human blood platelets .
|
-
-
- HY-118069
-
-
-
- HY-142050
-
|
Calcium Channel
|
Cardiovascular Disease
|
(R)-IDHP is an isomer of IDHP, a salvia metabolite that exerts vasorelaxant effects by inhibiting Ca 2+ release and Ca 2+ inward flow in voltage-dependent and receptor-operated calcium channels in vascular smooth muscle cells. IDHP is used in studies of cardiovascular disease .
|
-
-
- HY-123103
-
|
Lipoxygenase
Histamine Receptor
|
Inflammation/Immunology
|
Linetastine is an orally active and potent 5-Lipoxygenase inhibitor. Linetastine shows antihistamine activity. Linetastine inhibits leukotriene production and antagonizes the effect of histamine. Linetastine inhibits the release of leukotrienes B4 and C4 from calcium ionophore-stimulated human leukocytes .
|
-
-
- HY-120986
-
(S)-BEL; (S,E)-Bromoenol lactone
|
Phospholipase
|
Inflammation/Immunology
|
(S)-Bromoenol lactone ((S)-BEL) is an irreversible, chiral, mechanism-based inhibitor of calcium-independent phospholipase A2β (iPLA2β) that inhibits the vasopressin-induced release of arachidonate from cultured rat aortic smooth muscle (A10) cells with an IC50 of 2 µM .
|
-
-
- HY-138951
-
-
-
- HY-P1080
-
|
Calcium Channel
|
Neurological Disease
|
ω-Agatoxin IVA is a potent, selective P/Q type Ca 2+ (Cav2.1) channel blocker with IC50s of 2 nM and 90 nM for P-type and Q-type Ca 2+ channels, respectively. ω-Agatoxin IVA (IC50, 30-225 nM) inhibits glutamate exocytosis and calcium influx elicited by high potassium. ω-Agatoxin IVA also blocks the high potassium-induced release of serotonin and norepinephrine. ω-Agatoxin IVA has no effect on L-type or N-type calcium channels .
|
-
-
- HY-P1080A
-
|
Calcium Channel
|
Neurological Disease
|
ω-Agatoxin IVA TFA is a potent, selective P/Q type Ca 2+ (Cav2.1) channel blocker with IC50s of 2 nM and 90 nM for P-type and Q-type Ca 2+ channels, respectively. ω-Agatoxin IVA TFA (IC50, 30-225 nM) inhibits glutamate exocytosis and calcium influx elicited by high potassium. ω-Agatoxin IVA TFA also blocks the high potassium-induced release of serotonin and norepinephrine. ω-Agatoxin IVA TFA has no effect on L-type or N-type calcium channels .
|
-
-
- HY-109804
-
|
Reactive Oxygen Species
|
Inflammation/Immunology
|
CORM-401 is an oxidant-sensitive CO-releasing molecule. CORM-401 induces NO increase in the regulation of endothelial calcium signalling. CORM-401 reduces TNF-α/CHX and H2O2-induced ROS production. CORM-401 uncouples mitochondrial respiration and inhibits glycolysis .
|
-
-
- HY-13954
-
|
P2X Receptor
|
Neurological Disease
Inflammation/Immunology
|
A 839977 is a P2X7 selective antagonist; it blocks BzATP-evoked calcium influx at recombinant human, rat and mouse P2X7 receptors (IC50 values are 20 nM, 42 nM and 150 nM respectively) and reduces inflammatory and neuropathic pain in animal models; the antihyperalgesic effects of P2X7 receptor blockade are mediated by blocking the release of IL-1beta .
|
-
-
- HY-100403
-
|
mGluR
|
Cancer
|
Ro 67-7476 is a potent positive allosteric modulator of mGluR1 and potentiates glutamate-induced calcium release in HEK293 cells expressing rat mGluR1a with an EC50 of 60.1 nM . Ro 67-7476 is a potent P-ERK1/2 agonist and activates ERK1/2 phosphorylation in the absence of exogenously added glutamate (EC50=163.3 nM) .
|
-
-
- HY-N7491A
-
|
Calcium Channel
|
Cancer
|
ent-(+)-verticilide is a potent and selective inhibitor of cardiac ryanodine receptor (RyR2) calcium release channels with antiarrhythmic activity. ent-(+)-verticilide inhibits RyR2-mediated diastolic Ca 2+?leak and exhibits higher potency and a distinct mechanism of action compared with theDantrolene and Tetracaine.?ent-(+)-verticilide is a useful tool to investigate the therapeutic potential of targeting RyR2 hyperactivity in heart and brain pathologies .
|
-
-
- HY-B1231
-
RP-2831 hydrochloride
|
Others
|
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
Cancer
|
Heptaminol (RP-2831) hydrochloride is a vasoconstrictor used in the study of hypotension, especially orthostatic hypotension. Heptaminol is also a skin cancer proliferation inhibitor that inhibits immune inflammation induced by the tumor promoting factor 12-O-tetradecanoylphorbol-13-acetate (TPA) in an NO-dependent manner. Heptaminol also acts as a sympathomimetic amine, exerting indirect sympathetic effects. Heptaminol is also an antagonist of catecholamine release and uptake and can increase intracellular free calcium levels .
|
-
Cat. No. |
Product Name |
Type |
-
- HY-130575
-
|
Fluorescent Dyes/Probes
|
Fura-FF AM is a cell-permeable acetoxymethyl ester of fura-FF, a dluorescent calcium indicator. Fura-FF AM is hydrolyzed by intracellular esterases to release fura-FF in cells. Fura-FF is a difluorinated derivative of the calcium indicator fura-2. Compared to fura-2, fura-FF has a low affinity for calcium and is suitable for studying compartments with high concentrations of calcium.
|
-
- HY-101013
-
S-Nitroso-N-acetylpenicillamine
|
Fluorescent Dyes/Probes
|
D-SNAP (S-Nitroso-N-acetylpenicillamine) can Generate nitric oxide and form superoxides spontaneously under physiological conditions and is often used to probe the cell stress response and stimulate calcium-independent synaptic vesicle release.
|
Cat. No. |
Product Name |
Type |
-
- HY-100168
-
|
Biochemical Assay Reagents
|
BAPTA is a selective chelator for calcium. BAPTA, as calcium indicator, has high selectivity against magnesium and calcium. BAPTA is widely used as an intracellular buffer for investigating the effects of Ca 2+ release from intracellular stores or influx via Ca 2+-permeable channels in the plasma membrane. BAPTA can also inhibit phospholipase C activity independently of their role as Ca 2+ chelators .
|
-
- HY-100168B
-
|
Biochemical Assay Reagents
|
BAPTA tetrapotassium is a selective chelator for calcium. BAPTA, as calcium indicator, has high selectivity against magnesium and calcium. BAPTA tetrapotassium is widely used as an intracellular buffer for investigating the effects of Ca 2+ release from intracellular stores or influx via Ca 2+-permeable channels in the plasma membrane. BAPTA tetrapotassium can also inhibit phospholipase C activity independently of their role as Ca 2+ chelators .
|
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P3789
-
|
Peptides
|
Metabolic Disease
|
Prolactin-Releasing Peptide (12-31), rat is a fragment of the prolactin releasing peptide (PrRP). Prolactin-Releasing Peptide (12-31), rat shows high affinity for GPR10 receptors. Prolactin-Releasing Peptide (12-31), stimulates calcium mobilization in CHOK1 cells transfected with the PrRP receptor .
|
-
- HY-P1080A
-
|
Calcium Channel
|
Neurological Disease
|
ω-Agatoxin IVA TFA is a potent, selective P/Q type Ca 2+ (Cav2.1) channel blocker with IC50s of 2 nM and 90 nM for P-type and Q-type Ca 2+ channels, respectively. ω-Agatoxin IVA TFA (IC50, 30-225 nM) inhibits glutamate exocytosis and calcium influx elicited by high potassium. ω-Agatoxin IVA TFA also blocks the high potassium-induced release of serotonin and norepinephrine. ω-Agatoxin IVA TFA has no effect on L-type or N-type calcium channels .
|
-
- HY-P5494
-
|
Peptides
|
Others
|
DPc10 is a biological active peptide. (This is amino acids 2460 to 2495 fragment of cardiac ryanodine receptor (RyR2). RyR2 controls calcium release from the sarcoplasmic reticulum, which begins muscle contraction. Mutated RyR2 is associated to ventricular tachycardia (VT) and sudden death.)
|
-
- HY-138951
-
-
- HY-P1080
-
|
Calcium Channel
|
Neurological Disease
|
ω-Agatoxin IVA is a potent, selective P/Q type Ca 2+ (Cav2.1) channel blocker with IC50s of 2 nM and 90 nM for P-type and Q-type Ca 2+ channels, respectively. ω-Agatoxin IVA (IC50, 30-225 nM) inhibits glutamate exocytosis and calcium influx elicited by high potassium. ω-Agatoxin IVA also blocks the high potassium-induced release of serotonin and norepinephrine. ω-Agatoxin IVA has no effect on L-type or N-type calcium channels .
|
Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
Cat. No. |
Product Name |
Application |
Reactivity |
-
- HY-P83412
-
CRACM1; Orai 1; ORAI calcium release activated calcium modulator 1; orai1; ORAT1; Protein orai 1; TMEM142A
|
WB
|
Human |
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: